Current status of the treatment of degenerative mitral valve regurgitation

Detalhes bibliográficos
Autor(a) principal: Coutinho, Gonçalo
Data de Publicação: 2021
Outros Autores: Antunes, Manuel J.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10316/100809
https://doi.org/10.1016/j.repc.2020.10.011
Resumo: Degenerative mitral valve disease (myxomatous degeneration or fibroelastic deficiency) is the most common indication for surgical referral to treat mitral regurgitation. Mitral valve repair is the procedure of choice whenever feasible and when the results are expected to be durable. Posterior leaflet prolapse is the commonest lesion, found in up to two-thirds of patients. It is the easiest to repair, particularly when limited to one segment. In these cases, rates of repairability and procedural success approach 100%, and there is now ample evidence that the immediate and long-term results are better than those of valve replacement. Notably, minimally invasive valvular procedures, surgical or interventional, have attracted increasing interest in the last decade. When performed by experienced groups, mitral valve repair is unrivaled irrespective of the severity of lesions, from simple to complex, which leaflets are involved, and the type of degenerative involvement (myxomatous or fibroelastic). Its results should be viewed as the benchmark for other present and future technologies. By contrast, percutaneous mitral valve repair is still in its infancy and its results so far fall short of those of surgical repair. Nevertheless, continued investment in transcatheter procedures is of great importance to enable development and improved accessibility, particularly for patients who are considered unsuitable for surgery. In this review, we analyze the current status of management of degenerative mitral valve disease, discussing mitral valve anatomy and pathology, indications for intervention, and current surgical and transcatheter mitral valve procedures and results.
id RCAP_6edbe3ee49967825aad3a4b1c14b79d0
oai_identifier_str oai:estudogeral.uc.pt:10316/100809
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Current status of the treatment of degenerative mitral valve regurgitationDegenerative diseaseMitral valveMitral valve regurgitationMitral valve repairMitral valvuloplastySurgeryHumansMitral ValveTreatment OutcomeCardiac Surgical ProceduresMitral Valve InsufficiencyMitral Valve ProlapseDegenerative mitral valve disease (myxomatous degeneration or fibroelastic deficiency) is the most common indication for surgical referral to treat mitral regurgitation. Mitral valve repair is the procedure of choice whenever feasible and when the results are expected to be durable. Posterior leaflet prolapse is the commonest lesion, found in up to two-thirds of patients. It is the easiest to repair, particularly when limited to one segment. In these cases, rates of repairability and procedural success approach 100%, and there is now ample evidence that the immediate and long-term results are better than those of valve replacement. Notably, minimally invasive valvular procedures, surgical or interventional, have attracted increasing interest in the last decade. When performed by experienced groups, mitral valve repair is unrivaled irrespective of the severity of lesions, from simple to complex, which leaflets are involved, and the type of degenerative involvement (myxomatous or fibroelastic). Its results should be viewed as the benchmark for other present and future technologies. By contrast, percutaneous mitral valve repair is still in its infancy and its results so far fall short of those of surgical repair. Nevertheless, continued investment in transcatheter procedures is of great importance to enable development and improved accessibility, particularly for patients who are considered unsuitable for surgery. In this review, we analyze the current status of management of degenerative mitral valve disease, discussing mitral valve anatomy and pathology, indications for intervention, and current surgical and transcatheter mitral valve procedures and results.2021-04info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/100809http://hdl.handle.net/10316/100809https://doi.org/10.1016/j.repc.2020.10.011eng08702551Coutinho, GonçaloAntunes, Manuel J.info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-07-12T20:31:50Zoai:estudogeral.uc.pt:10316/100809Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:18:07.174084Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Current status of the treatment of degenerative mitral valve regurgitation
title Current status of the treatment of degenerative mitral valve regurgitation
spellingShingle Current status of the treatment of degenerative mitral valve regurgitation
Coutinho, Gonçalo
Degenerative disease
Mitral valve
Mitral valve regurgitation
Mitral valve repair
Mitral valvuloplasty
Surgery
Humans
Mitral Valve
Treatment Outcome
Cardiac Surgical Procedures
Mitral Valve Insufficiency
Mitral Valve Prolapse
title_short Current status of the treatment of degenerative mitral valve regurgitation
title_full Current status of the treatment of degenerative mitral valve regurgitation
title_fullStr Current status of the treatment of degenerative mitral valve regurgitation
title_full_unstemmed Current status of the treatment of degenerative mitral valve regurgitation
title_sort Current status of the treatment of degenerative mitral valve regurgitation
author Coutinho, Gonçalo
author_facet Coutinho, Gonçalo
Antunes, Manuel J.
author_role author
author2 Antunes, Manuel J.
author2_role author
dc.contributor.author.fl_str_mv Coutinho, Gonçalo
Antunes, Manuel J.
dc.subject.por.fl_str_mv Degenerative disease
Mitral valve
Mitral valve regurgitation
Mitral valve repair
Mitral valvuloplasty
Surgery
Humans
Mitral Valve
Treatment Outcome
Cardiac Surgical Procedures
Mitral Valve Insufficiency
Mitral Valve Prolapse
topic Degenerative disease
Mitral valve
Mitral valve regurgitation
Mitral valve repair
Mitral valvuloplasty
Surgery
Humans
Mitral Valve
Treatment Outcome
Cardiac Surgical Procedures
Mitral Valve Insufficiency
Mitral Valve Prolapse
description Degenerative mitral valve disease (myxomatous degeneration or fibroelastic deficiency) is the most common indication for surgical referral to treat mitral regurgitation. Mitral valve repair is the procedure of choice whenever feasible and when the results are expected to be durable. Posterior leaflet prolapse is the commonest lesion, found in up to two-thirds of patients. It is the easiest to repair, particularly when limited to one segment. In these cases, rates of repairability and procedural success approach 100%, and there is now ample evidence that the immediate and long-term results are better than those of valve replacement. Notably, minimally invasive valvular procedures, surgical or interventional, have attracted increasing interest in the last decade. When performed by experienced groups, mitral valve repair is unrivaled irrespective of the severity of lesions, from simple to complex, which leaflets are involved, and the type of degenerative involvement (myxomatous or fibroelastic). Its results should be viewed as the benchmark for other present and future technologies. By contrast, percutaneous mitral valve repair is still in its infancy and its results so far fall short of those of surgical repair. Nevertheless, continued investment in transcatheter procedures is of great importance to enable development and improved accessibility, particularly for patients who are considered unsuitable for surgery. In this review, we analyze the current status of management of degenerative mitral valve disease, discussing mitral valve anatomy and pathology, indications for intervention, and current surgical and transcatheter mitral valve procedures and results.
publishDate 2021
dc.date.none.fl_str_mv 2021-04
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10316/100809
http://hdl.handle.net/10316/100809
https://doi.org/10.1016/j.repc.2020.10.011
url http://hdl.handle.net/10316/100809
https://doi.org/10.1016/j.repc.2020.10.011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 08702551
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134076296232960